Targeting the novel ILT4 pathway.
Immunoglobulin-like transcript 4 (ILT4) is an immunosuppressive molecule expressed on myeloid cells and enriched in tumors. ILT receptors modulate the activity of innate and adaptive immune cells. In tumor cells, ILT4 plays a role in innate immune cell mechanisms that lead to tumor escape and ultimately tumor progression and metastasis making it a promising target for combination immuno-oncology treatments.
CHS-1000 is designed to block ILT4 activity and promote an active or proinflammatory response in the body.
CHS-1000 is an antibody designed to inhibit the ILT4 receptor to promote a proinflammatory immune response. CHS-1000 selectively binds to ILT4 with high affinity and potently blocks ILT4 interactions with its primary ligands. Functionally, CHS-1000 promotes re-polarization of suppressive myeloid cells to a pro-inflammatory phenotype and enhances activation of dendritic cells and T cells. Combinations of CHS-1000 with toripalimab-tpzi or other immunotherapy agents hold particular promise for enhanced anti-tumor activity.
Coherus anticipates filing an IND for CHS-1000 in the second quarter of 2024 with planned clinical development to include combination with toripalimab-tpzi for the treatment of various solid tumors. Coherus also plans to present the preclinical profile of CHS-1000 in Q2 2024.